Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation
|ClinicalTrials.gov Identifier: NCT01354964|
Recruitment Status : Unknown
Verified May 2011 by Albert Einstein College of Medicine, Inc..
Recruitment status was: Recruiting
First Posted : May 17, 2011
Last Update Posted : May 17, 2011
|Condition or disease||Intervention/treatment||Phase|
|Insulin Resistance||Drug: Vitamin D||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||March 2015|
Experimental: Vitamin D
Drug: Vitamin D
Weekly oral vitamin D drops, weight-based calculated dosage, taken on the same day each week for 4 months.
- Hepatic insulin sensitivity [ Time Frame: 2 and 4 months ]We will examine endogenous glucose production to assess hepatic insulin sensitivity.
- Peripheral insulin sensitivity [ Time Frame: 2 and 4 months ]We will examine the rate of glucose uptake to determine peripheral inslin sensitivity.
- Adipose tissue inflammatory markers/Cytokines in plasma [ Time Frame: 2 and 4 months ]Inflammatory markers-PAI-1, IL-6, TNF-a, iNOS
- Neuropsychological Testing [ Time Frame: 4 months ]We will conduct neuropsychological testing to assess cognitive function.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01354964
|Contact: Stephanie M Lawrence, BSfirstname.lastname@example.org|
|United States, New York|
|Albert Einstein College of Medicine of Yeshiva University||Recruiting|
|Bronx, New York, United States, 10461|
|Contact: Stephanie Lawrence, BS 718-430-2903 email@example.com|
|Principal Investigator: Preeti Kishore, MD|
|Principal Investigator:||Preeti Kishore, MD||Albert Einstein College of Medicine, Inc.|